Table 4.
Blood and urine markers in losartan- and placebo-treated patients
| Marker | Treatment assignment | Pre-treatment | Post-treatment | Change from baseline | P value |
|---|---|---|---|---|---|
| hsCRP (mg/l)* | Losartan | 2.6 | 2.0 | −34 % (−50 %, −13 %) | 0.07 |
| Placebo | 3.3 | 2.9 | −10 % (−32 %, 20 %) | ||
| VCAM-1 (ng/ml) | Losartan | 598 | 585 | −21 (−70, 28) | 0.10 |
| Placebo | 663 | 680 | 29 (−20, 79) | ||
| MCP-1 (pg/ml) | Losartan | 335 | 338 | −24 (−65, 18) | 0.62 |
| Placebo | 373 | 352 | −37 (−80, 6.8) | ||
| oxLDL (units/l) | Losartan | 50.2 | 39.8 | −5.5 (−11.9, 0.9) | 0.37 |
| Placebo | 41.4 | 39.8 | −2.0 (−8.1, 4.1) | ||
| F2-isoprostanes (ng/mg of creatinine) | Losartan | 2.1 | 3.1 | 0.9 (−0.4, 2.2) | 0.51 |
| Placebo | 1.7 | 2.5 | 0.4 (−0.9, 1.6) | ||
| E-selectin (ng/ml) | Losartan | 41.8 | 41.6 | −0.6 (−3.5, 2.3) | 0.55 |
| Placebo | 43.4 | 42.7 | −1.6 (−4.5, 1.3) | ||
| Urine albumin/creatine (mg/mmol) | Losartan | 1.0 | 1.4 | 0.2 (−0.3, 0.8) | 0.69 |
| Placebo | 1.2 | 1.5 | 0.4 (−0.1, 0.9) |
*
Geometric means and the geometric mean of the percentage change from baseline are reported.
Values are means (S.D.) or least-squares mean (95 % CI), unless otherwise stated. P values are a comparison between the groups for a change from the baseline value adjusted for baseline value and study site.